Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to -$1.3 billion.

  • Puma Biotechnology's Retained Earnings rose 277.16% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 277.16%. This contributed to the annual value of -$1.3 billion for FY2024, which is 225.09% up from last year.
  • As of Q3 2025, Puma Biotechnology's Retained Earnings stood at -$1.3 billion, which was up 277.16% from -$1.3 billion recorded in Q2 2025.
  • Puma Biotechnology's Retained Earnings' 5-year high stood at -$1.3 billion during Q3 2025, with a 5-year trough of -$1.4 billion in Q3 2021.
  • For the 5-year period, Puma Biotechnology's Retained Earnings averaged around -$1.3 billion, with its median value being -$1.4 billion (2024).
  • In the last 5 years, Puma Biotechnology's Retained Earnings tumbled by 371.33% in 2022 and then skyrocketed by 357.7% in 2025.
  • Over the past 5 years, Puma Biotechnology's Retained Earnings (Quarter) stood at -$1.4 billion in 2021, then increased by 0.0% to -$1.4 billion in 2022, then rose by 1.58% to -$1.3 billion in 2023, then rose by 2.25% to -$1.3 billion in 2024, then grew by 1.34% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.3 billion for Q2 2025, and -$1.3 billion during Q1 2025.